Literature DB >> 15024957

Positron emission tomography imaging of brain tumors.

Alexander M Spence1, David A Mankoff, Mark Muzi.   

Abstract

Energy metabolism and amino acid transport and incorporation are important components of the pathophysiology of gliomas, about which molecular imaging is providing regional biologic information that is useful to clinical practice. Imaging hypoxia is straightforward and proliferation imaging with FLT shows significant promise. Neither has been exploited thoroughly enough to allow judgement of their potential benefit to the practice of neuro-oncology. Although cell division is the most distinguishing function of growth in tumors, probing membrane biosynthesis with PET and 1-[11C]acetate or a choline tracer may yield information as helpful as protein or DNA synthesis. Because astrocytic gliomas frequently carry epidermal growth factor receptor mutations at a frequency that is related to grade, a PET tracer that is specific for this mutated receptor could be useful for grading and prognosis [35]. Methods for imaging angiogenesis are being developed; 18F-labeling of a cyclic RGD-containing glycopeptide, cyclo(-Arg-Gly-Asp-D-Phe-Lys(sugar amino acid)-), with 4-nitro-phenyl 2-[18F]fluoropropionate has been reported [136]. 18F-labeled annexin V is being tested as a new PET agent for quantitating tumor cell death and predicting response to therapy. Annexin V binds to surface membranes that have exposed phosphatidyl serine residues resulting from programmed cell destruction. Recently, a Tc-99m-labeled derivative has been shown to accumulate in late stage lung cancer and lymphoma in response to chemotherapy [137]. As molecular pathways leading to and sustaining neoplasia become better understood, so will our capacity improve to measure them in vivo and intervene to the patient's advantage.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15024957     DOI: 10.1016/s1052-5149(03)00097-2

Source DB:  PubMed          Journal:  Neuroimaging Clin N Am        ISSN: 1052-5149            Impact factor:   2.264


  6 in total

1.  In vivo detection of tumor boundary using ultrahigh-resolution optical coherence angiography and fluorescence imaging.

Authors:  Jiang You; Chelsea Pan; Kicheon Park; Ang Li; Congwu Du
Journal:  J Biophotonics       Date:  2019-12-23       Impact factor: 3.207

2.  Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response.

Authors:  Bradford A Moffat; Thomas L Chenevert; Theodore S Lawrence; Charles R Meyer; Timothy D Johnson; Qian Dong; Christina Tsien; Suresh Mukherji; Douglas J Quint; Stephen S Gebarski; Patricia L Robertson; Larry R Junck; Alnawaz Rehemtulla; Brian D Ross
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-01       Impact factor: 11.205

3.  Prognostic significance of parameters derived from co-registered 18F-fluorodeoxyglucose PET and contrast-enhanced MRI in patients with high-grade glioma.

Authors:  M J Paldino; T Z Wong; D A Reardon; H S Friedman; D P Barboriak
Journal:  Br J Radiol       Date:  2010-10-19       Impact factor: 3.039

4.  Prognostic significance of growth kinetics in newly diagnosed glioblastomas revealed by combining serial imaging with a novel biomathematical model.

Authors:  Christina H Wang; Jason K Rockhill; Maciej Mrugala; Danielle L Peacock; Albert Lai; Katy Jusenius; Joanna M Wardlaw; Timothy Cloughesy; Alexander M Spence; Russ Rockne; Ellsworth C Alvord; Kristin R Swanson
Journal:  Cancer Res       Date:  2009-11-24       Impact factor: 12.701

5.  [11C] methionine and [18F] fluorodeoxyglucose PET in the follow-up of glioblastoma multiforme.

Authors:  Christian Pötzi; Alexander Becherer; Christine Marosi; Georgios Karanikas; Monika Szabo; Robert Dudczak; Kurt Kletter; Susanne Asenbaum
Journal:  J Neurooncol       Date:  2007-05-11       Impact factor: 4.506

6.  Identification of early and distinct glioblastoma response patterns treated by boron neutron capture therapy not predicted by standard radiographic assessment using functional diffusion map.

Authors:  Ryo Hiramatsu; Shinji Kawabata; Motomasa Furuse; Shin-Ichi Miyatake; Toshihiko Kuroiwa
Journal:  Radiat Oncol       Date:  2013-08-01       Impact factor: 3.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.